Suppr超能文献

心血管疾病与糖尿病肾脏疾病。

Cardiovascular Disease and Diabetic Kidney Disease.

机构信息

Department of Diabetes, Central Clinical School, Monash University, Melbourne, Australia.

Department of Diabetes, Central Clinical School, Monash University, Melbourne, Australia.

出版信息

Semin Nephrol. 2018 May;38(3):217-232. doi: 10.1016/j.semnephrol.2018.02.003.

Abstract

Diabetic kidney disease commonly is associated with an increased risk of cardiovascular disease. There are traditional common risk factors for both conditions including hypertension and poor glycemic control. However, it is likely that there are other pathophysiological mechanisms that explain the clinical phenomenon of increased cardiovascular disease in diabetic patients with chronic kidney and vice versa. Current management of both conditions includes aggressive glucose and blood pressure control. The protective role of treating dyslipidemia has been shown for cardiovascular disease, but the results for renal disease are not as clear. The advent of new classes of glucose-lowering agents such as sodium glucose co-transporter2 inhibitors and glucagon-like peptide-1 agonists has resulted in impressive effects on both cardiovascular and renal disease in diabetes. However, how these drugs act independently of glucose lowering to confer both kidney and cardiovascular protection has not been fully elucidated. Nevertheless, these new treatments provide optimism for reducing both microvascular and macrovascular complications in diabetes, which represent the major causes of morbidity and premature mortality in this condition.

摘要

糖尿病肾病通常与心血管疾病风险增加相关。这两种疾病都有高血压和血糖控制不佳等传统共同危险因素。然而,很可能还有其他病理生理机制可以解释糖尿病患者慢性肾脏病和反之亦然的心血管疾病增加的临床现象。目前,这两种疾病的治疗都包括积极控制血糖和血压。治疗血脂异常对心血管疾病有保护作用,但对肾脏疾病的结果则不那么明确。新型降糖药物如钠-葡萄糖共转运蛋白 2 抑制剂和胰高血糖素样肽-1 激动剂的出现,对糖尿病患者的心血管和肾脏疾病均产生了显著效果。然而,这些药物如何在不降低血糖的情况下独立发挥作用,从而同时保护肾脏和心血管,尚未完全阐明。尽管如此,这些新的治疗方法为减少糖尿病的微血管和大血管并发症提供了希望,这些并发症是该疾病发病率和过早死亡的主要原因。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验